Acneiform eruption due to erlotinib treatment: a case report: Acneiform eruption due to erlotinib treatment

Deniz Duman Günsay; Asena Çiğdem Doğramacı

doi:10.5281/zenodo.17156217

Authors

Deniz Duman Günsay Defne State Hospital
Asena Çiğdem Doğramacı Mustafa Kemal University, Faculty of Medicine, Dermatology

DOI:

https://doi.org/10.5281/zenodo.17156217

Keywords:

Acne, Acneiform eruptıon, Erlotinib

Abstract

Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the tyrosine kinase activity of EGFR and is used in the treatment of advanced non-small cell lung cancer. Common mucocutaneous side effects reported with erlotinib treatment are xeroderma, pruritus and paronychia, with acneiform eruption being the most common. Erlotinib-associated acneiform eruption usually occurs within the first 1-3 weeks of drug use, typically as asymptomatic or pruritic erythematous papules and/or pustules on the face, chest, abdomen and thighs. Here, we report a 56-year-old woman with non-small cell lung cancer who developed erlotinib-associated acneiform eruption.

References

1. Gridelli, C., Bareschino, M. A., Schettino, C., ve ark. (2007: Erlotinib in Non Small Cell Lung Cancer Treatment: Current Status and Future Development. The Oncologist, 12, 840-849. DOI. 10.1634/theoncologist.12-7-840

2. Bareschino, M. A., Schettino, C., Troiani, T., ve ark. (2007: Erlotinib in cancer treatment. Annals of Oncology, 18. 35:41. 10.1093/annonc/mdm222

3. Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. : Clinical presentation and pathophysiology of EGFR inhibitor-induced dermatologic toxicities. Oncology (Williston Park). 2007 Nov;21(11 Suppl 5):4-9.. 56:317-326. 10.1016/S1040-8428(07)80111-7

4. Segaert, S., & van Cutsem, E. (2005: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology. 16:1425-1433. 10.1093/annonc/mdi279

5. Osio, A., Mateus, C., Soria, J., ve ark. (2009: Cutaneous side effects in patients on long term treatment with epidermal growth factor receptor inhibitors. British Journal of Dermatology. 161:515-521. 10.1111/j.1365-2133.2009.09214.x

6. Balagula, Y., Garbe, C., Myskowski, P., ve ark. (2011: Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. International Journal of Dermatology. 50:129-146. 10.1111/j.1365-4632.2010.04791.x

7. Lacouture, M. E. (2006: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer. 6:803-812. 10.1038/nrc1970

8. Lacouture, M. E., Anadkat, M. J., Bensadoun, R. J., ve ark. (2011: Clinical practice guidelines for the prevention and treatment of EGFR inhibitor associated dermatologic toxicities. Supportive Care in Cancer. 19:1079-1095. 10.1007/s00520-011-1197-6

9. Lacouture, M. E., Sibaud, V., & Gerber, P. A. (2021: Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines. Annals of Oncology. 32:157-170. 10.1016/j.annonc.2020.11.005

10. Tsimboukis, P. (2013: Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clinical Lung Cancer. 14:12-19. 10.1016/j.cllc.2012.08.003

11. Yoshioka, M. (2014: Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non small cell lung cancer. Lung Cancer. 86:201-207. 10.1016/j.lungcan.2014.09.015

12. Nakahara T, Moroi Y, Takayama K, Ishii N, Furue M: Acneiform eruption induced by epidermal growth factor receptor inhibitor erlotinib. J Dermatol. 2011, 38:975-976. 10.1111/j.1346-8138.2011.01220.x

13. Metin A, Elmas Ö, Tüzün Y: Erlotinib'e bağlı akneiform döküntü: Olgu sunumu. Cumhuriyet Med J. 2014, 36:74-77. 10.7197/cmj.v36i1.56326

Acneiform eruption due to erlotinib treatment: a case report